What’s the latest on sulphonylureas in the management of type 2 diabetes?
Sulphonylureas act by binding to sulphonylurea receptors and stimulating insulin secretion from pancreatic beta cells. This class of oral hypoglycaemic agents is still widely used in the management of type 2 diabetes in patients where lifestyle changes alone are insufficient. Although the older-gene...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2013-12-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/3945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Sulphonylureas act by binding to sulphonylurea receptors and stimulating insulin secretion from pancreatic beta cells. This class of oral hypoglycaemic agents is still widely used in the management of type 2 diabetes in patients where lifestyle changes alone are insufficient. Although the older-generation sulphonylureas no longer have a place in therapy, the newer-generation sulphonylureas are a widely recognised choice, either as monotherapy, or in combination with insulin and/or other oral hypoglycaemic agents. |
|---|---|
| ISSN: | 2078-6190 2078-6204 |